一项联邦授权增强了SCLC治疗选择,通过新的疗法和早期发现改善了生存。 A federal mandate has boosted SCLC treatment options, improving survival through new therapies and early detection.

小型细胞肺癌(SCLC)曾经是治疗很少的最致命癌症之一,由于2013年的联邦授权将低存活率癌症的研究列为优先事项,因此正在取得重大进展。 Small cell lung cancer (SCLC), once among the deadliest cancers with few treatments, is seeing major progress due to a 2013 federal mandate prioritizing research for low-survival-rate cancers. 这导致治疗方案增加67%,包括由林业发展局批准的治疗方案,如Tarlatamab和Lurbinectedin,以及在临床试验中有前途的下一代方法。 This has led to a 67% increase in treatment options, including FDA-approved therapies like Tarlatamab and Lurbinectedin, and promising next-generation approaches in clinical trials. 通过筛查早期发现至关重要,像Wendy Brooks这样的病人,由于家庭史的早期发现,由于试验,在诊断后年复一年地存活下来。 Early detection through screening is critical, and patients like Wendy Brooks, identified early due to family history, are surviving years post-diagnosis thanks to trials. 美国肺癌基金会提倡筛查、研究和提高认识, 以改善结果。 Doctors report longer remissions and even potential cures, with the Lung Cancer Foundation of America advocating for screening, research, and awareness to improve outcomes.